Results 81 to 90 of about 4,153 (212)

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1997-2026, March 2026.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani   +5 more
wiley   +1 more source

Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis. [PDF]

open access: yes
AIMS: Hypokalaemia is associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). This exploratory FIDELITY analysis, a prespecified pooled patient-dataset from FIDELIO-DKD and FIGARO-DKD, investigated the incidence
Agarwal, Rajiv   +11 more
core   +1 more source

Mineralocorticoid Receptor Antagonists in the Treatment of Coronary Artery Disease, Myocardial Infarction and Heart Failure [PDF]

open access: yes, 2019
Affecting sodium reabsorption and potassium excretion in the kidney, mineralocorticoid receptor antagonists (MRA) were originally developed as antihypertensive drugs.
Bauersachs, Johann, Zwadlo, Carolin
core   +2 more sources

Construction of a prognostic assessment model for diabetic nephropathy based on serum fibrinogen and renal tissue IFTA score

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 3, Page 448-459, March 2026.
ABSTRACT Objective To explore the association between serum fibrinogen (FIB) and clinicopathological features and renal prognosis in type 2 diabetic nephropathy (T2DN), and develop a web‐based dynamic model to predict renal progression. Methods This paper retrospectively enrolled 173 biopsy‐proven T2DN patients and stratified them by the optimal FIB ...
Lin Ning   +5 more
wiley   +1 more source

Single‐Chain Anti‐IL‐1β Antibody Carried by Outer Membrane Vesicles of Bacteroides fragilis Alleviates Tubular Inflammation in Chronic Kidney Disease

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 2, February 2026.
Engineered Bacteroides fragilis outer membrane vesicles carrying anti‐IL‐1β scFv and kidney‐targeting peptides alleviate renal inflammation and injury in CKD mouse models via precise delivery and NF‐κB inhibition. ABSTRACT Microinflammation is a key driver of chronic kidney disease (CKD) progression, with interleukin‐1β (IL‐1β) playing a pivotal role ...
Liang Li   +6 more
wiley   +1 more source

Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison

open access: yesJournal of Market Access & Health Policy
This study aimed to close an evidence gap concerning the relative efficacy of finerenone versus SGLT2is in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Canagliflozin was selected as a proxy for the SGLT2i class.
David Cherney   +6 more
doaj   +1 more source

Combination therapy for kidney disease in people with diabetes mellitus [PDF]

open access: yes
Diabetic kidney disease (DKD), defined as co-existing diabetes and chronic kidney disease in the absence of other clear causes of kidney injury, occurs in approximately 20–40% of patients with diabetes mellitus.
Bjornstad, Petter   +12 more
core   +1 more source

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial [PDF]

open access: yes, 2019
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease.
Abdel-Rahman, Emaad   +1067 more
core   +2 more sources

Effect of Finerenone on the KCCQ in patients with HFmrEF/HFpEF: a prespecified analysis of FINEARTS-HF [PDF]

open access: yes
Background: Patients with heart failure (HF) are limited by symptoms and have impaired quality of life. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a patient-reported outcome measure that enables evaluation of the effect of HF and the impact ...
Atherton, John J.   +24 more
core   +2 more sources

Home - About - Disclaimer - Privacy